Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Background: Since the introduction of new systemic treatments for metastatic melanoma, early detection of recurrent disease in AJCC stage III patients has become of increasing importance. Therefore the demand for FDG-PET-CT scans is rising, with some protocols even implementing standard scanning.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.